Meeting
2022 ASCO Annual Meeting
The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
Authors
Nyelia Williams
The Ohio State University, Columbus, OH
Nyelia Williams , Rebecca Hoyd , Caroline E. Wheeler , Mari Lynn , Amna Bibi , Shannon Gray , Michael Bodner , Namrata Arya , Scott Roberts , Phuong Hoang , Jessica Apparicio , Deanna Merrill , Richard Cheng Han Wu , Claire F. Verschraegen , Christin Elizabeth Burd , Kari Lynn Kendra , Daniel Spakowicz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT05102773
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9568)
DOI
10.1200/JCO.2022.40.16_suppl.9568
Abstract #
9568
Poster Bd #
161
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A retrospective study of ipilimumab plus nivolumab in anti–PD-L1/PD-1-refractory merkel cell carcinoma.
First Author: Sophia Z. Shalhout
Poster
2016 ASCO Annual Meeting
Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).
First Author: Alexander Noor Shoushtari
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin